Хроническая сердечная недостаточность у женщин: особенности течения и медикаментозной терапии
![Диссертация: Хроническая сердечная недостаточность у женщин: особенности течения и медикаментозной терапии](https://westud.ru/work/5101944/cover.png)
Апробация работы проведена на совместном заседании кафедр скорой медицинской помощи ФПДО, Клинической функциональной диагностики ФПДО, внутренних болезней стоматологического факультета МГМСУ, кафедры кардиологии и общей терапии ФГУ «Учебно-научный медицинский центр Управления Делами Президента РФ», лаборатории клинической кардиологии ФГУ «НИИ физико-химической медицины Росздрава» и ГКБ № 68… Читать ещё >
Содержание
- Список сокращений и определений
- Глава I. Обзор данных литературы
- 1. 1. Хроническая сердечная недостаточность: определение, 16 этиология, клиническая классификация
- 1. 2. Тендерные особенности хронической сердечной 20 недостаточности
- 1. 3. Генетический полиморфизм генов эстрогеновых рецепторов 47 и тендерные различия в развитии сердечно-сосудистой патологии
- Глава II. Материалы и методы исследования
- 2. 1. Характеристика больных
- 2. 2. Методы исследования
- Глава III. Клинико-статистический анализ тендерных 82 особенностей хронической сердечной недостаточности
- 3. 1. Клинико-статистический анализ хронической сердечной 82 недостаточности в многопрофильном стационаре
- 3. 2. Клинико-статистический анализ хронической сердечной 92 недостаточности в наркологическом стационаре
- Глава IV. Клинико-гемодинамическая характеристика 96 хронической сердечной недостаточности у женщин и ее динамика на фоне различных схем фармакотерапии
- 4. 1. Структурно-функциональное состояние левого желудочка у 96 женщин с хронической сердечной недостаточностью
- 4. 2. Клиническая эффективность блокатора кальциевых каналов 101 амлодипина в лечении хронической сердечной недостаточности с сохраненной ФВЛЖ у женщин
- 4. 3. Сравнительная клиническая эффективность бета- 109 адреноблокаторов карведилола, бисопролола и небиволола в лечении хронической сердечной недостаточности у женщин
- 4. 4. Сравнительная клиническая эффективность ингибиторов АПФ 124 рамиприла и эналаприла в лечении хронической сердечной недостаточности с сохраненной ФВЛЖ у женщин
4.5 Клинико-гемодинамическая характеристика и клиническая 133 эффективность монотерапии ингибитором АПФ периндоприлом или бета-адреноблокатором карведилолом хронической сердечной недостаточности у женщин на фоне зависимости от алкоголя
Глава V. Комплексный анализ эффективности фармакотерапии и 151 определение клинико-лабораторных предикторов неблагоприятных исходов хронической сердечной недостаточности у женщин
5.1 Многофакторный регрессионный анализ эффективности 151 различных бета-адреноблокаторов в терапии хронической сердечной недостаточности у женщин в зависимости от исходных клинико-демографических показателей
5.2 Возможность использования лабораторных показателей 156 нейрогормонального статуса для выбора бета-адреноблокатора у женщин, страдающих хронической сердечной недостаточностью
5.3 Многофакторный регрессионный анализ эффективности 166 блокатора кальциевых каналов амлодипина в терапии женщин с хронической сердечной недостаточностью
5.4 Возможность прогнозирования прогрессирования 168 хронической сердечной недостаточности у женщин на основании многофакториого пошагового регрессионного анализа
5.5 Факторное. моделирование клинических исходов хронической 173 сердечной недостаточности у женщин
Глава VI. Клинико-генетический анализ различных типов 211 полиморфизма генов эстрогеновых рецепторов и хронической сердечной недостаточности у женщин
Глава VII. Обсуждение полученных результатов
Выводы
Список литературы
- Агеев Ф.Т., Константинова Е. В., Овчинников А. Г. Ингибиторы ангиотензинпревращающего фермента краеугольный камень лечения сердечной недостаточности // РМЖ. 1999. Т. 7. № 2. С. 21−25.
- Атрощенко Е.С. Пациент с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. //Журнал Сердечная Недостаточность. 2007. — Том 8. — № 6. — С. 297−300.
- Барац С.С., Закроева А. Г. Диастолическая функция сердца по показателям трансмитрального кровотока и потока в легочных венах: дискуссионные вопросы патогенеза, терминологии и классификации. Кардиология 1998- 5: 69−76.
- Бащинский С.Е., Осипов М. А. Диагностическая ценность изучения диастолической функции левого желудочка при проведении стресс-допплер-эхокардиографии у больных ишемической болезнью сердца. Кардиология 1991- 9: 28—31.
- Бекжанова Ж.С., Беркинбаев С. Ф., Жолдин Б. К. Структура ХСН по данным госпитализации и обращаемости. Тезисы III конгресса ОССН «Сердечная недостаточность'2008» С. 34−35.
- Бляхман Ф.А., Честухин В. В., Шумаков В. И. Асинхронизм как модулятор сократимости миокарда и насосной функции левого желудочка // Из кн.: Очерки по физиологии. Под ред. В. И. Шумакова. М.: Медицина, 1998. С. 235.
- Бююль А., Цефель П. SPSS: искусство обработки информации, Москва, 2005, Издательство «DiaSoft», 602 с.
- Гладких А.С., Савина Н. М., Кудинова С. П., Байдина О. И., Сидоренко Б. А. Прогноз больных с ХСН: повторные госпитализации, продолжительность стационарного лечения и госпитальная смертность. Тезисы III конгресса ОССН «Сердечная недостаточность"2008» С. 15.
- Добротворская Т.Е., Супрун Е. К., Шуков А. А. Влияние эналаприла на систолическую и диастолическую функцию левого желудочка при застойной сердечной недостаточности. Кардиология 1994- 12: 106—12.
- Жаров Е. И., Зиц С. В. Значение спектральной допплер-эхокардиографии в диагностике и оценке тяжести синдрома застойной сердечной недостаточности//Кардиология 1996- 1:47−50.
- Желнов В.В., Павлова И. Ф., Симонов В. И., Батищев А. А. Диастолическая функция левого желудочка у больных ишемической болезнью сердца. Кардиология 1993- 5: 12—4.
- Женщины и мужчины России. Статистический сборник. 2004. М.: Росстат, 2005. с. 70.
- Жиров И.В. Алкоголь и сердечная недостаточность. Часть I. Алкоголь как фактор риска сердечно-сосудистых заболеваний.//Журнал Сердечная Недостаточность. 2004. — Том 5. — № 5. — С. 252−255.
- Жиров И.В., Винникова М. А., Агибалова Т. В. Алкоголь и женское сердце: влияние на сердечно-сосудистую заболеваемость и сердечнососудистый континуум.//Сердце. 2006. — Т.5. — № 7. — С. 364−367.
- Жиров И.В., Сарбалинова Т. К. Алкоголь и сердечная недостаточность. Часть 2. Дилатационная и алкогольная кардиомиопатия сходство и различия.//Журнал Сердечная Недостаточность. — 2004. — Том 5. — № 6. — С. 308−310.
- Задионченко В. С., Кольцов П. А. Фармакотерапия сердечнососудистых заболеваний в амбулаторно-поликлинической практике. Москва -Издательство: Анахарсис, 2005 г., 208 с.
- Задионченко B.C., Холодкова Н. Б., Нестеренко О. И. и др. Коррекция эндотелиальной дисфункции у больных хроническим легочным сердцем антагонистами рецепторов ангиотензина II. РФК 2007- 2:48−52 .
- Закирова А.Н., Альбеева З. Р., Карамова И. М., Фахретдинова Е. Р. Хроническая сердечная недостаточность в клинической практике в Республике Башкортостан. //Журнал Сердечная Недостаточность. 2008. -Том 9. — № 3. — С. 104−106.
- Каленич О. Ремоделирование миокарда основное звено в развитии недостаточности кровообращения при миокардитах // Российский кардиологический журнал. 1999. № 3. С. 810.
- Крикунов П.В., Васюк Ю. А., Копелева М. В., Крикунова О. В. Гипертрофия левого желудочка как мишень для терапевтического вмешательства. Особенности диагностики и лечения. //Сердце. 2008. — Том 7.-№ 4.-С. 324−334.
- Курбанов Р.Д., Курбанов Н. А., Абдуллаев Т. А. и др. Значение клинико-функциональных проявлений в прогнозе жизни больных дилатационной кардиомиопатией//Журнал Сердечная недостаточность 2003- 3- 147−148.
- Кушаковский М. С. Хроническая застойная сердечная недостаточность. Санкт-Петербург. 1998- 319 с.
- Маколкин В.И., Овчаренко С. И. Внутренние болезни: Учебник. 2005. — М, Медицина — 591 с.
- Мартынов А.И., Мухин Н. А. Внутренние болезни (2 тома), 2004 -М.:Гэотар
- Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). //Журнал Сердечная Недостаточность. — 2007. Том 8. — № 1. — С. 4−41.
- Никитин Н.П., Алявин A.JI. Особенности диастолической дисфункции в процессе ремоделирования левого желудочка сердца при хронической сердечной недостаточности //Кардиология 1998- 3: 56 61.
- Никитин Н.П., Алявин А. Л., Голоскокова В. Ю., Маджитов Х. Х. Особенности процесса позднего ремоделирования сердца у больных, перенесших инфаркт миокарда, и их прогностическое значение // Кардиология. 1999. № 1. С.54−58.
- Никулина Н.Н., Якушин С. С., Бойцов С. А., Акинина С. А., Фурменко Г. И., Лиферов Р. А. Проблемы статистической регистрации смертности от ХСН в Российской Федерации. Тезисы III конгресса ОССН «Сердечная недостаточность"2008» С. 53.
- Овчинников А.Г., Агеев Ф. Т., Мареев В. Ю. Методические аспекты применения Допплер-эхокардиографии в диагностике диастолической дисфункции левого желудочка. // Сердечная недостаточность. 2000. — Т.1, № 2.-С. 66−70.
- Подзолков В.И. Хроническая сердечная недостаточность у женщин в постменопаузе. Медицинские аспекты здоровья женщин 2007:1(4).
- Поливода С.Н., Черепок А. А. Фактор Виллебранда как маркер эндотелиальной дисфункции у пациентов с заболеваниями сердечнососудистой системы. Укр. ревматол. журн. 2000−7:13−17.
- Порошина Е.А., Тарловская Е. И. Эпидемиология артериальной гипертонии и сердечной недостаточности в Кировской области: динамика2002−2007. Тезисы III конгресса ОССН «Сердечная недостаточность'2008» -С. 11.
- Постникова С.Л. Ингибиторы ангиотензинпревращающего фермента в кардиологической практике // РМЖ. 2004. № 7. С. 18−21.
- Седов В.П., Алехин М. Н., Божьев A.M. Метод автоматического количественного акустического анализа в оценке диастолической функции левого желудочка. Визуализация в клинике 2000. N16. — С. 46−51.
- Сидоренко Б.А., Преображенский Д. В. Гипертрофия левого желудочка: патогенез, диагностика и возможность обратного развития под влиянием антигипертензивной терапии. Кардиология, 1998- 38(5): 80−85.
- Смирнова Е.А., Якушин С. С. Распространенность и лечение хронической сердечной недостаточности среди населения Рязанской области. //Журнал Сердечная Недостаточность. 2003. — Том 5. — № 6. — С. 289−291.
- Стрюк Р.И., Длусская И. Г. Адренореактивность и сердечно-сосудистая система. М.: Медицина, 2003. — 160 с.
- Терещенко С.Н. Тендерные стратегии в терапии хронической сердечной недостаточности миф или необходимость? Сердце, 2006. — Том 5.-№ 7.-С. 360−363.
- Терещенко С.Н., Атрощенко Е. С., Жиров И. В. Особенности патогенеза и фармакотерапии хронической сердечной недостаточности у женщин./ЛСардиология. 2006. — Т. 46. — № 10. — С. 30−35.
- Терещенко С.Н., Джаиани Н. А., Жиров И. В., Ускач Т. М. Хроническая сердечная недостаточность. Вопросы диагностики и лечения. М.: «Анахарсис», 2006 72 с.
- Шутов A.M., Кондратьева Н. И., Ивашкина Т. Н. и др. Диастолическая дисфункция и клинические проявления сердечной недостаточности у больных с додиализной хронической почечной недостаточностью. Нефрология 2001- 4: 30−34.
- Шутов A.M., Куликова Е. С., Ивашкина Т. Н., Кондратьева Н. И. Анемия и диастолическая функция левого желудочка у больных с додиализной хронической почечной недостаточностью. Нефрология и диализ 2001- 4: 422 426.
- Щербинина Е.В., Бадин Ю. В., Вайсберг А. Р., Фомин И. В., Поляков Д. С. Динамика этиологических причин формирования ХСН за 9 лет наблюдения (1998−2007 гг). Тезисы III конгресса ОССН «Сердечная недостаточность'2008» С. 108.
- Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology, and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996−28:1781−8.
- Agoston I, Cameron CS, Yao D, Dela Rosa A, Mann DL, Deswal A. Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction. Am J Cardiol 2004- 94:1003−7.
- Anand IS, Fisher LD, Chiang Y-T, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003−107: 1278−83.
- Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005- 112:1428−34.
- Angermann C., Costard-Jaeckle A., Deng M. et al. Is carvedilol safe and efficacious in severe heart failure patients accepted for heart transplantation. J Heart Lung Transplant 2001- 20(2) — 250−251.
- Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic function, and hemodynamic staging. Circulation 2003−107:1991−7.
- Antolini L, Nam B-H, D’Agostino RB. Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Comm Statist Theory Methods 2004−33:2117−35.
- Arab S, Gramolini AO, Ping P, et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006−48:1733−41.
- Askanas A, Udoshi M, Sadjadi S The heart in chronic alcoholism: a noninvasive study//Am Heart J 1980- 99- 9−16.
- Aurigemma G., Gaasch W. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology 1995−86:310−317.
- Aurigemma G., Gaasch W. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology 1995 -86−310−317.
- Aurigemma GP, Gaasch WH, Villegas B, Meyer ТЕ. Noninvasive assessment of left ventricular mass, chamber volume, and contractile function. Curr Probl Cardiol 1995−20:361−440.
- Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med 2004−351:1097−105.
- Australia/New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997- 349- 375−380.
- Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JG. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol 2002−39:138−41.
- Barbier CE, Bjerner T, Johansson L, Lind L, Ahlstrom H. Myocardial scars more frequent than expected: magnetic resonance imaging detects potential risk group. J Am Coll Cardiol 2006−48:765−71.
- Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptoralpha during cardiac hypertrophic growth. J Clin Invest 2000−105:1723−30.
- Barjon JN, Rouleau J-L, Bichet D, et al. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol 1987−9:622−30.
- Bello N., Mosca L. Epidemiology of Coronary Heart Disease in Women. Prog Cardiovasc Dis 2004- 46- 287−295.
- Benjamin E, Levy D, Vasiri S. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham heart study. J Am Med Assoc 1994−271:840−4.
- Benjamin E, Wolf P, D’Agostino R. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998−97:946−52.
- Bergstroem A, Andersson B, Edner M, et al. Carvedilol improves diastolic function in patients with diastolic heart failure. For the SWEDIC Investigators. Circulation 2001−104- 718.
- Berry С, Hogg К, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 2005−91:907−13.
- Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006−355:260−9.
- Boneu В., Abbal M., Plante J., Bierme R. Factor VIII complex and endothelial damage. Lancet 1975−30:325−333.
- Bowie E.J.W., Solberg L.A., Fass D.N. et al. Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J. Clin. Invest. 1986−78:26−30.
- Burkhoff D, Maurer M, Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation 2003−107:656−8.
- Carroll J., Carroll E., Feldman T. et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992−86−1099−1107.
- Caruana L, Petrie MC, Davie AP, Mc-Murray JJ. Do patients with suspected heart failure and preserved left ventricular systolic dysfunction suffer from «diastolic heart failure» or from misdiagnosis? A prospective descriptive study. BMJ 2000−321:215−8.
- Casademont J, Miro O. Electron transport chain defects in heart failure. Heart Fail Rev 2002−7:131−9.
- Chandler MP, Kerner J, Huang H, et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 2004−287:H1538-H1543.
- Chen HH, Lainchbuiy JG, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 2002−8:279−87.
- Chen YT, Vaccarino V, Williams CS, et al. Risk factors for heart failure in the elderly: a prospective community based study. Am J Med 1999−106:605−9.
- CIBIS Investigators and Committees. A randomized trial of P-blockade in heart failure: the Cardiac Bisoprolol Insufficiency Study (CIBIS). Circulation 1994- 90: 1765−73.
- Cicoira M, Rossi A, Bonapace S, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004−10:403−11.
- Cohn J., Fowler M., Bristow M. et al. Safety and efficacy of carvedilol in severe heart failure. US Carvedilol Heart Failure Study Group. J Card Fail 1997- 3- 173−179.
- Cohn JN, Johnson G. Heart failure with normal ejection fraction: the V-HeFT Study. Circulation 1990−81:Suppl 111:111−48−111−53.
- Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001−345:1667−75.
- Colucci W., Packer M., Bristow M. et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996- 94- 2800−2806.
- Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991−338:973−6.
- Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007- 115:928−35.
- Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003−42:736−42.
- Dancy M, Leech G, Bland J et al. Preclinical left ventricular abnormalities in alcoholic are independent of nutritional status, cirrhosis and cigarette smoking//Lancet 1985- 1- 1122−1125
- Dandona P., Karne R., Ghanim H. et al. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to aminoacids. Circulation 2000- 101- 122−124.
- Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007−50:2357- 68.
- Davies MK, Hobbs FDR, Davis RC- et al. Prevalence of LV systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: a population based study. Lancet 2001−358:439−44.
- Davila-Roman VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002- 40:271−7.
- Davis M. Impact of gender on drug responses. Drug Topics 1998- 142:91 100.
- Dayer M, Cowie MR. Heart failure: diagnosis and healthcare burden. Clin Med 2004- 4: 13−8.
- De Keulenaer GW, Brutsaert DL Dilated cardiomyopathies: changing pathophysiological concepts and mechanisms of dysfimction//J Card Surg 1999- 4, 64−74.
- De Keulenaer GW, Brutsaert DL. Diastolic heart failure: a separate disease or selection bias? Prog Cardiovasc Dis. 2007−49:275−283.
- De Sousa E, Veksler V, Minajeva A, et al. Subcellular creatine kinase alterations: implications in heart failure. Circ Res 1999−85:68−76.
- Di Lenarda A., Sabbadini G., Salvatore L. et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy wit persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999- 33(7) — 19 261 934.
- Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005−91:161−5.
- Domingues-Montanari S, Subiranal, Tomas M, Marrugat J et al. Association between ESR2 Genetic Variants and Risk of Myocardial Infarction.// Clinical Chemistry. -2008 (5), 1183−1189.
- Doughty R., Whalley G., Walsh H. et al. Effects of carvedilol on left ventricular remodeling in patients following acute myocardial infarction: the CAPRICORN echo substudy. Circulation 2001- 104 (17 Suppl) — 517.
- Eichorn E., Gheorghiade M. Digoxin new perspective on an old drug. N Engl J Med 2002−347- 1394−1395.
- Elkayam U, Weber L, McKay C, et al. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol 1985−56:560−6.
- Emberson JR, Ng LL, Armitage J, et al. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007−49:311−9.
- Essop MF, Opie LH. Metabolic therapy for heart failure. Eur Heart J 2004−25: 1765−8.
- Ewenstein B.M., Warhol M.J., Handin R.I., Pober J.S. Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J. Cell. Biol. l987−104:1432−1433.
- Fauchier L, Babuty D, Poret P, et al Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy//Eur Heart J 2000- 21- 306−314.
- Fauchier L. Alcoholic cardiomyopathy and ventricular arrhythmias//Chest 2003- 123- 1320−1324.
- Ferlinz J, Gallo CT. Responses of patients in heart failure to long-term oral verapamil administration. Circulation 1984−70:Suppl 11:11−305.
- Fernandez-Sola J, Estruch R, Nicolas J-M et al. Comparison of alcoholic cardiomyopathy in women versus men//Am J Cardiol 1997- 80,481−48.
- Fernandez-Sola J, Estruch R, Nicolas J-M et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997- 80, 481−48.
- Fernandez-Sola J., Nicolas J., Para J. et al. Diastolic function impairment in alcoholics//Alcohol Clin Exp Med 2000- 24- 1830−1835.
- Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003- 100:1226−31.
- Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006- 116:615−22.
- Fischer M., Baessler A., Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002−53:672−677.
- Fischer M., Baessler A., Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002−53−672−677.
- Fox KF, Cowie MR, Coats AJS, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001−22:228−36.
- Gamier A, Fortin D, Delomenie C, Momken I, Veksler V, Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 2003−551:491−501.
- Gavazzi A, De Maria R, Parolini M et al. On behalf of the Italian Multicenter Cardiomyopathy Study Group (SPIC) Alcohol abuse and cardiomyopathy in men//Am J Cardiol 2000- 85- 1114−1118.
- Gilbert E., Abraham W., Olsen S. Et al. Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996- 94(11) — 28 172 825.
- Gillum R.F. Heart failure in the United States, 1970−1985//Am. Heart J 1987- 113−1043−1045.
- Giugliano D., Acampora R., Marfella R. et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized control trial. Ann Intern Med 1997- 126(12) — 955−959.
- Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. Ann Intern Med 2002−137:631−9.
- Green D., Kucuk O., Haring O., Dyer A. The factor VIII complex in atherosclerosis: effects of aspirin. J. Chronic. Diseases. 1982−34:21−26.
- Grieve DJ, Shah AM. Oxidative stress in heart failure: more than just damage. Eur Heart J 2003−24:2161−3.
- Gronnesby JK, Borgan O. A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal 1996−2:315−28.
- Guerra S., Leri A., Wang X. Et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999−85−856−866.
- Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broadspectrum anti-inflammatory approaches. Am J Cardiol 2005−95:Suppl:17c-23c.
- Gustafsson F, Torp-Pedersen C, Brendorp B, Seibaek M, Burchardt H, Kober L. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J 2003−24:863−70.
- Halm MA, Penque S. Heart failure in women. Prog Cardiovasc Nurs 2000−15:121−33.
- Hardy С J, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial highenergy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991−122:795−801.
- Harris KM et al. Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006- 114: 216−225.
- Hatle L. How to diagnose diastolic heart failure a consensus statement. Eur Heart J. 2007−28:2421−2423.
- He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women. Arch Intern Med 2001- 161:996−1002.
- Heart Disease and Stroke Statistics2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009−119-e21-el81.
- Heitmann M., Davidsen U., Stokholm K. Et al. Renal and cardiac function during alphal-beta-blockade in congestive heart failure. Scand J Clin Lab Invest 2002- 62(2) — 97−104.
- Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004−109:1729−34.
- Hentonnen A, Kortelainen M, Kunnas T, Nikkari S. Estrogen receptor-1 genotype is related to coronary intima thickness in young to middle-aged women.//Scand J Clin Lab Invest.-- 2007 67 (4), 380−386.
- Hernandez AF, Velazquez EJ, Solomon SD, et al. Left ventricular assessment in myocardial infarction: the VALIANT registry. Arch Intern Med 2005−165:2162−9.
- Ho K, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 1993−88:107−15.
- Ho K., Pinsky J., Kannel W. et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993−22−6A-13A.
- Hodges Y, Tung L, Yan X, Graham J et al. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects.//Circulation 2000 (10), 1792−1798.
- Hoffman R, Psaty BM, Kronmal RA. Modifiable risk factors for incidence of heart failure in the Coronary Artery Surgery Study. Arch Intern Med 1994−154:417−24.
- Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function- epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004−43:317−27.
- Hugel S, Horn M, de Groot M, et al. Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol 1999−277:H2167-H2175.
- Hulsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998−32:1695−700.
- Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 2004−95:568−78.
- Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004−95:135−45.
- Jessup M., Pina I. Is it important to examine gender differences in the epidemiology and outcome of severe heart failure? J Thorac Cardiovasc Surg 2004- 127- 1247−1252.
- Jochmann N., Stangl K., Garbe E. et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular disease. Eur. Heart J. 2005- 26:15 851 595.
- Jones RC, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. J Am Coll Cardiol 2004−44:1025−9.
- Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002−162:1689−94.
- Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007−49:1733−9.
- Kalsi KK, Smolenski RT, Pritchard RD, Khaghani A, Seymour AM, Yacoub MH. Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Eur J Clin Invest 1999−29: 469−77.
- Kameda K, Matsunaga T, Abe N, et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Eur Heart J 2003−24:2180−5.
- Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocystinemia in humans. Circulation 1999−100: 1161−8.
- Kannel W., McDee D. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979−241−2035−2038.
- Kannel WB, D’Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med 1999−159:1197−1204.
- Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol 2002−11:101−7.
- Kasper E., Willem W., Hutchins G. et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients//J Am Coll Cardiol 1994- 23- 586−590.
- Katritsis D., Panagiotakos D., Karvouni E. et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003 -92- 111 6—1119.
- Keating G., Jarvis B. Carvedilol. A review of its use in chronic heart failure. Drugs 2003- 63 (16) — 1697−1741.
- Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007−50: 1054−60.
- Khand A., Rankin A., Martin W. et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003 -42- 1944−1951.
- Khuchua ZA, Ventura-Clapier R, Kuznetsov AV, Grishin MN, Saks VA. Alterations in the creatine kinase system in the myocardium of cardiomyopathic hamsters. Biochem Biophys Res Commun 1989- 165: 748−57.
- King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res 2003−92:177−85.
- Kinny E, Wright R, Caldwell J Risk factors in alcoholic cardiomyopathy//Angiol J Vase Dis 1989- 4- 270−275.
- Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005- 112:1756−62.
- Kittleson MM, St. John ME, Bead V, et al. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart 2007−93: 365−7.
- Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. Am J Cardiol 2001- 87:413−9.
- Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 2002−7:17−27.
- Kloner R., Sowers J., DiBona G. et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996−77:713−722.
- Ко D, Tu JV, Masoudi FA, et al. Quality of care and outcomes of older patients with heart failure hospitalized in the United States and Canada. Arch Intern Med 2005−165:2486−92.
- Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997−278:212−6.
- Krum H., Ninio D., MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 2000- 84- 615−619.
- Krum H., Roecker E., Mohasci P. Et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 2003- 289(6) — 712−718.
- Krum H., Sackner-Bernstein J., Goldsmith R. et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995- 92(6) — 1499−1506.
- Krumholz H., Larson M., Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993−72:310−313.
- Krumholz HM, Wang Y, Parent EM, Mockalis J, Petrillo M, Radford MJ. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med 1997- 157:2242−7.
- Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S et al. Cloning of a novel receptor expressed in rat prostate and ovary.// Proceedings of the National Academy of Sciences. 1996 (9), 5925−5930.
- Kupari M, Koskinen P, Suokas A et al. Left ventricular filling impairment in asymptomatic chronic alcoholics//Am J Cardiol 1990- 66- 1473−1477.
- Kurtz DM, Rinaldo P, Rhead WJ, et al. Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci U S A 1998−95:15 592−7.
- La Vecchia L, Bedogni F, Bozzola L et al. Predication of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters//Clin Cardiol 1996- 19- 45−50.
- Lam CS et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007−115:1982−1990.
- Lamb HJ, Beyerbacht HP, van der Laarse A, et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999−99:2261−7.
- Laser A, Ingwall JS, Tian R, et al. Regional biochemical remodeling in noninfarcted tissue of rat heart post-myocardial infarction. J Mol Cell Cardiol 1996−28: 1531−8.
- Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004−25:292−9.
- Lazarevi? A, Nakatani S, Nekovi9 A et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking//J Am Coll Cardiol 2000- 35- 1599−1606.
- Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003−290:2581−7.
- Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005−20:201−10.
- Lehtimaki T, Kunnas T, Mattila K, Koivula T, Karhunen P. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study.//J. Mol Med. 2002 80(3), 176−180.
- Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004- 25:1214−20.
- Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002−347:1397−402.
- Levy D., Larson M., Vasan R. et al. The progression from hypertension to congestive heart failure. JAMA 1996−275−1557−1662.
- Lloyd-Jones D. The risk of congestive heart failure. Sobering lessons from the Framingham heart study. Curr Cardiol Rep 2001−3:184−90.
- Lloyd-Jones D., Larson M., Leip E. et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002−106−3068−3072.
- Lo JC, Zhao X, Scuteri A, Brockwell S et al. The association of genetic polymorphisms in sex hormone biosynthesis and action with insulin sensitivity and diabetes mellitus in women at midlife.// Am J Med. 2006 (1), 69−78.
- Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004−43:635−41.
- Lopaschuk GD, Rebeyka IM, Allard MF. Metabolic modulation: a means to mend a broken heart. Circulation 2002- 105:140−2.
- Lu H, Higashikata T, Inazu A, Nohara A et al. Association of estrogen receptor-alpha gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia.//JAMA, 2002, 817−823.
- Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002−347:161−7.
- Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005−111:2837−49.
- Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004- 109:1594−602.
- Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol 2005−95:Suppl:9C-16C.
- Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003−349: 1587−9.
- Mansur P, Nogueira CC, Strunz CM, Aldrighi JM et al. Genetic polymorphisms of estrogen receptors in patients with premature coronary artery disease. //Arch Med Res. 2005(3), 511−517.
- Marin-Garcia J, Goldenthal MJ, Мое GW. Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovasc Res 2001−52: 103−10.
- Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003 -41:217−23.
- Masson S, Latini R, Anand IS, et al. The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2006- 12:375−80.
- Mathews E, Gradin J, Henry W et al. Echocardiography abnormalities in chronic alcoholics with and without overt congestive heart failure//Am J Cardiol 1981- 47, 570−578.
- Matsuda N., Endo Y., Uchida Y. et al. Plasma brain natriuretic peptide levels predict tolerance to carvedilol in patients with severe heart failure. Circulation 2000- 102 (18 Suppl 2) — 627−628.
- McCullough PA, Khandelwal AK, McKinnon JE, et al. Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America. Congest Heart Fail 2005- 11:6−11.
- McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007−28:829−35.
- McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971 -285:1441−6.
- McKenna C, Codd M, McCann H et al. Alcohol consumption idiopathic dilated cardiomyopathy: a case control study//Am Heart J 1998- 135- 833−837.
- McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003−362:767−71.
- McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005- 365: 1877−89.
- Meibohm В., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics. Clin. Pharmacokinet. 2002−41:329−342.
- Mendez L., Davidoff R., Cupples L. Et al. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997−134:207−212.
- Merritt J., Niebaur M., Tarakji K. et al. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003−92−735−736.
- Mestroni L, Rocco С et al. Advances in molecular genetics of dilated cardiomyopathy//Cardiology Clinics 1998- 16- 603−609.
- Michels V., Driscoll D, Miller F. et al. Progression of familial and non-familial dilated cardiomyopathy: long term follow up//Heart 2003- 89- 757−761.
- Mohasci P., Fowler M., Krum H. et al. Should physician avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study. Circulation 2001- 104 (Suppl. 2) — 754.
- Moller CS, Zethelius B, Sundstrom J, Lind L. Impact of follow-up time and remeasurement of the electrocardiogram and conventional cardiovascular risk factors on their predictive value for myocardial infarction. J Intern Med 2006−260: 22−30.
- Montalescot G., Philippe F., Vicaut E. and the French Investigators of the ESSENCE Trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Circulation. 1998−98:294−299.
- Moyssakis I., Pantazopoulos N., Hallaq Y. et al. Left ventricular systolic and diastolic indices in dilated cardiomyopathy with biventricular involvement versus isolated left ventricular involvement//Chest 2003- 124- 185S.
- Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004−350:647−54.
- Murakami Y, Zhang Y, Clio YK, et al. Myocardial oxygenation during high work states in hearts with postinfarction remodeling. Circulation 1999−99:942−8.
- Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004−364:1786−8,
- Nagele H., Bohlmann M., Eck U. et al. Combination therapy with carvedilol and amiodarone in patients with severe heart failure. Eur J Heart Fail 2000−2-71−79.
- Nahrendorf M, Spindler M, Ни K, et al. Creatine kinase knockout mice show left ventricular hypertrophy and dilatation, but unaltered remodeling post-myocardial infarction. Cardiovasc Res 2005−65:419−27.
- Nakamura К., Kusano К., Nakamura Y. et al. Carvedilol decreases elevated oxidative stress in human failing miocardium. Circulation 2002- 105(24) — 28 672 871.
- Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997- 96:2190−6.
- Neubauer S, Horn M, Naumann A, et al. Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest 1995−95:1092−100.
- Neubauer S, Horn M, Pabst T, et al. Contributions of 3 IP-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 1995−16:Suppl 0:115−8.
- Neubauer S, Remkes H, Spindler M, et al. Downregulation of the Na (+)-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 1999−100:1847−50.
- Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J et al. Mechanisms of estrogen action.// Physiological Review. ~ 2001 (8), 1535−1565.
- Ning XH, Zhang J, Liu J, et al. Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction. J Am Coll Cardiol 2000−36:282−7.
- Oakley C. Peripartum cardiomyopathy. In: Women&Heart Disease, 2nd edition. Eds: WengerN. and Collins P. London: Taylor&Francis, 2005, 341−350.
- Ohtsuka Т., Hamada M., Saeki H. et al. Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2002- 89(8) — 996−999.
- Olivetti G., Giordano G., Corradi D. Et al. Gender differences and aging: effects on the human heart. J Am Coll Cardiol 1995−26:1068−1079.
- Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol 2007−50:205−14.
- Opasich С, Tavazzi L, Lucci D, et al. Comparison of one-year outcomes in women versus men with chronic congestive heart failure. Am J Cardiol 2000−86:353−7.
- Osorio JC, Stanley WC, Linke A, et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002−106:606−12.
- Over J., Sixma J.J. et al. Survival of 125-iodine labeled factor VIII in normals and patients with classical hemophilia. Observations on the heterogeneity of human factor VIII. J. Clin. Invest 1978−62:223−234.
- Owan T, Redfleld M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005−47:320−32.
- Owan ТЕ, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006−355:251−9.
- Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996−334:1349−55.
- Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far. Circulation 1987−75:Suppl V: V56-V64.
- Packer M, Lee WH, Medina N, et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol 1987−10:1303−11.
- Packer M, Lee WH, Medina N, Yushak M. Comparative negative inotropic effects of nifedipine and diltiazem in patients with severe left ventricular dysfunction. Circulation 1985−72:Suppl 111:111−275.
- Packer M, Nicod P, Khandheria BR, et al. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. J Am Coll Cardiol 1991−17:Suppl A:274A.
- Packer M., Bristow M., Cohn J. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996- 334(21) — 1349−1355.
- Packer M., Coats A., Fowler M. et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001- 344(22) — 1651−1658.
- Packer M., Colucci W., Sackner-Bernstein J. et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996- 94- 2793−2799.
- Packer M., O’Connor C., Ghali J. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996−335−1107−1114.
- Parkash R, Maisel WH, Toca FM, Stevenson WG. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am Heart J 2005- 150:701−6.
- Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008−27:157−72.
- Pencina MJ, D’Agostino RB. Overall С as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004−23:2109−23.
- Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004−159:882−90.
- Pernenkil R, Vinson JM, Shah AS, Beckham V, Wittenberg C, Rich MW. Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol 1997−79: 216−9.
- Pfeffer J., Pfeffer M., Fletcher P. et al. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol 1982−242:H776-H784.
- Pfeffer MA, Braunwald E. Ventricular remodeling following myocardial infarction: experimental observations and clinical implications. Circulation 1990−81:1161−72.
- Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003−362:759−66.
- Philbin EF, Rocco ТА Jr, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000- 109:60 513.
- Piano M. Alcoholic cardiomyopathy. Incidence, clinical characteristics and pathophysiology. Chest 2002- 121- 1638−1650.
- Pitt В., Zannad F., Remme W. et al. The Randomized Aldactone Evaluation Study Investigators The Effect of Spironolactone on Morbidity and Mortality in
- Patients with Severe Heart Failure //N. Engl. J. Med. 1999 — Vol. 341. — P. 709 -717.
- Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006−27:65−75.
- Prazak P, Pfisterer M, Osswald S et al. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic cardiomyopathy//Eur Heart J 1996- 17- 251−257.
- Pritchett AM et al. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol. 2005−45:87−92.
- Rathore S., Wang Y., Krumholz H. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002−347−1403−1411.
- Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001- 104: 2923−31.
- Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003−289:194−202.
- Redfield MM. Heart failure — an epidemic of uncertain proportions. N Engl J Med 2002- 347:1442−4.
- Refsgaard J., Andreasen F., Goetzsche O. Improvement of endothelial dysfunction in patients with chronic heart failure during treatment with carvedilol. Eur Heart J 1999- 20 Suppl- 375.
- Reldy M.A., Chopek M., Chao S. et al. Injury induces increase of von Willebrand factor in rat endothelial cells. Amer. J. Pathology 1989−134:857−864.
- Remme W. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN): rationale and design. CARMEN Steering Committee. Cardiovasc Drugs Ther 2001- 15- 69−77.
- Remondino A, Rosenblatt-Velin N, Montessuit C, et al. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol 2000−32:2025−34.
- Richardson P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies// Circulation 1995- 93, 841−842.
- Ridha M., Makikallio Т., Lopera G. et al. Effects of carvedilol on heart rate dynamics in patients with congestive heart failure. Ann Noninvasive Electrocardiol 2002- 7(2) — 133−138.
- Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007−297:611- 9.
- Riedinger M, Dracup K, Brecht ML. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. Am J Crit Care 2002−11:211−19.
- Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004−292:344−50.
- Rossig L., Haendeler J., Mallat Z. et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 2000- 36(7) — 2081−2089.
- Ruggery Z.M., Ware J. Von Willebrand factor. FASEB J.1993−52:1005−1011.
- Sack MN, Rader ТА, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996- 94:2837−42.
- Sanderson JE. Heart failure with a normal ejection fraction. Heart. 2007−93:155−158.
- Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000−99:27−35.
- Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992−20:301−6.
- Schuit SC, Oei HS, Witteman JC, van Kessel CH, van Meurs JBJ et al. Estrogen receptor alpha gene polymorphisms and the risk of myocardial infarction.//JAMA.- 2004, 2969 -2977.
- Senior R., Basu S., Kinsey C. et al. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999- 137(4) — 646−652.
- Senni M, Redfield MM. Heart failure with preserved systolic function: a different natural history? J Am Coll Cardiol 2001−38:1277−82.
- Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998−98:2282−9.
- Setaro JF, Soufer R, Remetz MS, Perlmutter RA, Zaret BL. Long-term outcome in patients with congestive heart failure and intact systolic left ventricular performance. Am J Cardiol 1992- 69:1212−6.
- Shahar E, Lee S, Kim J, Duval S, Barber C, Luepker RV. Hospitalized heart failure: rates and long-term mortality. J Card Fail 2004−10:374−9.
- Shearman A, Cupples L. Estrogen receptor alpha gene variation and cardiovascular disease-editorial//JAMA. 2003, 2252.
- Shearman A, Cupples L, Demissie S, Peter I, Schmid С et al. Association between estrogen receptor alpha gene variation and cardiovascular disease.//JAMA. 2003, 2263−2270.
- Silberbauer K, Juhasz M, Ohrenberger G et al. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in young alcoholics//Cardiology 1988- 75- 431−439.
- Simon T, Mary-Krause M, Funck-Bretano C, et al. Sex differences in the prognosis of congestive heart failure. Results from the cardiac insufficiency bisoprolol study (CIBIS II). Circulation 2001−102:375−80,
- Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003- 41:1510−8.
- Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005−112:3738−44.
- Sowers MR, Symons JP, Jannausch ML, Chu J et al. Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-l from the Study of Women’s Health Across the Nation (SWAN).// Am J Med. 2006 (1), 61−68.
- Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations fromthe ' Global Registry of Acute. Coronary Events (GRACE). Circulation 2004−109:494−9-: .
- Stewart:S., McMurray J., Hebbom A. et al. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. Eur Heart J 2002- 23 Suppl- 136.
- Suzuki T, Hayashi D, Yainazaki T, et alt Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998- 136:362−3.341 • Taegtmeyer H. Metabolism — the lost child of cardiology. J Am Coll Cardiol 2000−36:1386−8. ,
- Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003−108:2964−6:
- Tarantini L, Faggiano P, Senni M, et al. Clinical features and- prognosis: associated with: a: preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by
- Taylor M, Wallhaus TR, Degrado TR, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with 18 °F.fluoro-6-thia-heptadecanoic acid and [18FJFDG in patients with congestive heart failure. J: Nucl Med 2001−42:55−62-.
- Teerlink JR., Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr Heart Fail Rep 2005−2:191−7. .
- The AIRE Study Investigators. Lancet. 1993−342:821−828.
- The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in: patients with left-ventricular dysfunction: the CAPmCORN randomized triah Lancet 2001- 357- 1385−1390- /
- The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987- 316: 1429−35.
- The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988−319:385−92.
- Towbin J, Bowie S, Ortiz-Lopez R, Wang Q. Genetic basis of dilated cardiomyopathy//Cardiomyopathies 1999- 56−65.
- Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004−44:1970−6.
- Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vase Pharmacol 2005−3: 221−9.
- Van Heerebeek L et al. Myocardial structure and function* differ in systolic and diastolic heart failure. Circulation. 2006- 113:1966−73.
- Varadarajan P, Pai RG. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. J Card Fail 2003−9:107−12.
- Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995−26: 1565−74.
- Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricularejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999−33:1948−55.
- Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000- 101:2118−21.
- Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003- 107: 1486−91.
- Ventura-Clapier R, Gamier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004- 555:1−13.
- Venugopal SK, Deveraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005−14:33−7.
- Verweij C.L. Biosynthesis of human von Willebrand factor. Haemostasis 1988−18:224−245.
- Vital and Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services. Centers for Disease Control and Prevention, October 1995- 13(122).
- Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001−103:2441−6.
- Wang J et al. Left Ventricular Untwisting Rate by Speckle Tracking Echocardiography. Circulation. 2007−116:2580−2586.
- Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006−355:2631−9.
- Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006−355:2615−7.
- Weinberg E., Thienelt C., Katz S. et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 1999−34:264−273.
- Witchitz S, Haiat R, Tarrade T, et al. Accidents cardio-vasculaires au cours des traitements par le verapamil: a propos de 6 observations. Nouv Press Med 1975−4:337−8.
- Wohlin M, Helmersson J, Sundstrom J, et al. Both cyclooxygenase- and cytokinemediated inflammation are associated with carotid intima-media thickness. Cytokine 2007−38:130−6.
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003−362:777−81.
- Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008−358: 2107−16.
- Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment. Circulation 2002−105:1503−8.
- Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001−104:779−82.
- Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003−41:1519−22.